FDA Brief

Warning letters Drugs

FDA warning letter to

PMS4PMS, LLC

High riskIssued Apr 7, 2025Posted Apr 15, 2025Center for Drug Evaluation and Research (CDER)

FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.

What happened

FDA inspected the drug manufacturing facility at 4255 Research Pkwy, Clarence, NY, from November 4 to 8, 2024. Investigators found no testing of finished batches for identity and strength of the active ingredient before release, no stability program to support the 5-year expiration date, and a quality unit that did not oversee production. Reviewing the label, FDA also found "Comforté® Menstrual Cramp RELIEF CREAM" claims relief of menstrual cramp pain, which is not an allowed use for external analgesic drugs sold without approval.

What FDA found

  1. The firm did not test each batch for the identity and strength of its active ingredient before releasing it for sale.

    21 CFR 211.165(a)
  2. The firm had no stability testing to show the product would still meet specifications through its labeled 5-year expiration date.

    21 CFR 211.137(a)
  3. The quality unit did not do its job: there were no written procedures for its duties, for qualifying raw material suppliers, or for testing incoming ingredients.

    21 CFR 211.22(a) and 211.22(d)
  4. Production operators were not adequately trained in CGMP for OTC drugs.

    21 CFR 211.25(a)
  5. The firm lacked adequate written master production and control records to keep batches uniform.

    21 CFR 211.186(a)
  6. The product is labeled to relieve menstrual cramp pain, a use not covered by the OTC external analgesic monograph, so it is an unapproved new drug and misbranded.

    FD&C Act sections 505(a) and 502(ee), 21 U.S.C. 355(a) and 352(ee)

What FDA wants

Respond in writing within 15 working days describing what you have done to fix the violations and prevent recurrence, including how you will address product already on the market that is still within expiry. Also state whether you will resume drug manufacturing here, and notify FDA before restarting; FDA recommends a qualified CGMP consultant.

Who should pay attention

  • brands and retailers selling Comforté-labeled OTC creams
  • contract manufacturers of OTC topical drug products
  • companies that relied on this firm's release and stability testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk